These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26476543)

  • 21. Genomics of chronic neutrophilic leukemia.
    Maxson JE; Tyner JW
    Blood; 2017 Feb; 129(6):715-722. PubMed ID: 28028025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spliceosome mutations in hematopoietic malignancies.
    Hahn CN; Scott HS
    Nat Genet; 2011 Dec; 44(1):9-10. PubMed ID: 22200771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.
    Sallman DA; Komrokji R; Vaupel C; Cluzeau T; Geyer SM; McGraw KL; Al Ali NH; Lancet J; McGinniss MJ; Nahas S; Smith AE; Kulasekararaj A; Mufti G; List A; Hall J; Padron E
    Leukemia; 2016 Mar; 30(3):666-73. PubMed ID: 26514544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.
    Jawhar M; Schwaab J; Schnittger S; Meggendorfer M; Pfirrmann M; Sotlar K; Horny HP; Metzgeroth G; Kluger S; Naumann N; Haferlach C; Haferlach T; Valent P; Hofmann WK; Fabarius A; Cross NC; Reiter A
    Leukemia; 2016 Jan; 30(1):136-43. PubMed ID: 26464169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies.
    Taylor J; Lee SC
    Genes Chromosomes Cancer; 2019 Dec; 58(12):889-902. PubMed ID: 31334570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
    Thol F; Kade S; Schlarmann C; Löffeld P; Morgan M; Krauter J; Wlodarski MW; Kölking B; Wichmann M; Görlich K; Göhring G; Bug G; Ottmann O; Niemeyer CM; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
    Blood; 2012 Apr; 119(15):3578-84. PubMed ID: 22389253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing.
    Patnaik MM; Lasho TL; Finke CM; Hanson CA; King RL; Ketterling RP; Gangat N; Tefferi A
    Am J Hematol; 2016 May; 91(5):492-8. PubMed ID: 26874914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Splicing Factor Mutations in Cancer.
    Bejar R
    Adv Exp Med Biol; 2016; 907():215-28. PubMed ID: 27256388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia.
    Engle EK; Fisher DA; Miller CA; McLellan MD; Fulton RS; Moore DM; Wilson RK; Ley TJ; Oh ST
    Leukemia; 2015 Apr; 29(4):869-76. PubMed ID: 25252869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML.
    Hirabayashi S; Flotho C; Moetter J; Heuser M; Hasle H; Gruhn B; Klingebiel T; Thol F; Schlegelberger B; Baumann I; Strahm B; Stary J; Locatelli F; Zecca M; Bergstraesser E; Dworzak M; van den Heuvel-Eibrink MM; De Moerloose B; Ogawa S; Niemeyer CM; Wlodarski MW;
    Blood; 2012 Mar; 119(11):e96-9. PubMed ID: 22238327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive genomic profiling reveals molecular subsets of
    Johnson SM; Haberberger J; Galeotti J; Ramkissoon L; Coombs CC; Richardson DR; Foster MC; Duncan D; Montgomery ND; Ferguson NL; Zeidner JF
    Leuk Lymphoma; 2024 Feb; 65(2):209-218. PubMed ID: 37921062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies.
    Kroeze LI; Nikoloski G; da Silva-Coelho P; van Hoogen P; Stevens-Linders E; Kuiper RP; Schnittger S; Haferlach T; Pahl HL; van der Reijden BA; Jansen JH
    Blood; 2012 Feb; 119(5):1318-9. PubMed ID: 22308284
    [No Abstract]   [Full Text] [Related]  

  • 33. Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria.
    Shen W; Clemente MJ; Hosono N; Yoshida K; Przychodzen B; Yoshizato T; Shiraishi Y; Miyano S; Ogawa S; Maciejewski JP; Makishima H
    J Clin Invest; 2014 Oct; 124(10):4529-38. PubMed ID: 25244093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Establishing the Ion Torrent PGM Sequencing Methods for the Clinical Diagnosis of MPN Patients].
    Huang JX; Li YL; Xu N; Yin CX; Zhou X; Pan CY; He BL; Lu ZY; Liu QF; Liu XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1744-1750. PubMed ID: 29262909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation.
    Magor GW; Tallack MR; Klose NM; Taylor D; Korbie D; Mollee P; Trau M; Perkins AC
    J Mol Diagn; 2016 Sep; 18(5):707-718. PubMed ID: 27449473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.
    Puda A; Milosevic JD; Berg T; Klampfl T; Harutyunyan AS; Gisslinger B; Rumi E; Pietra D; Malcovati L; Elena C; Doubek M; Steurer M; Tosic N; Pavlovic S; Guglielmelli P; Pieri L; Vannucchi AM; Gisslinger H; Cazzola M; Kralovics R
    Am J Hematol; 2012 Mar; 87(3):245-50. PubMed ID: 22190018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.
    Zhang SJ; Rampal R; Manshouri T; Patel J; Mensah N; Kayserian A; Hricik T; Heguy A; Hedvat C; Gönen M; Kantarjian H; Levine RL; Abdel-Wahab O; Verstovsek S
    Blood; 2012 May; 119(19):4480-5. PubMed ID: 22431577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New mutations and pathogenesis of myeloproliferative neoplasms.
    Vainchenker W; Delhommeau F; Constantinescu SN; Bernard OA
    Blood; 2011 Aug; 118(7):1723-35. PubMed ID: 21653328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutational landscape of chronic myelomonocytic leukemia and its potential clinical significance.
    Han W; Zhou F; Wang Z; Hua H; Qin W; Jia Z; Cai X; Chen M; Liu J; Chao H; Lu X
    Int J Hematol; 2022 Jan; 115(1):21-32. PubMed ID: 34449040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms.
    Przychodzen B; Jerez A; Guinta K; Sekeres MA; Padgett R; Maciejewski JP; Makishima H
    Blood; 2013 Aug; 122(6):999-1006. PubMed ID: 23775717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.